These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 29860606)

  • 1. Cangrelor use prior to left ventricular assist device surgery: a case series.
    Washam JB; Yerokun B; Patel CB; Welsby IJ; Milano CA; DeVore AD
    J Thromb Thrombolysis; 2018 Aug; 46(2):131-133. PubMed ID: 29860606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of cangrelor with heparin for left ventricular assist device implantation in a patient with acute heparin-induced thrombocytopenia.
    Gernhofer YK; Ross M; Khoche S; Pretorius V
    J Cardiothorac Surg; 2018 Apr; 13(1):30. PubMed ID: 29665860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Intravenous P2Y12-Receptor Inhibition with Cangrelor in Patients Presenting with Acute Coronary Syndrome and Cardiogenic Shock - a Case Series.
    Droppa M; Borst O; Rath D; Müller K; Gawaz M; Bhatt DL; Geisler T
    Cell Physiol Biochem; 2017; 42(4):1336-1341. PubMed ID: 28700987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of Cangrelor as a Bridge to Left Ventricular Assist Device Implantation in a Patient with a Recent Drug-Eluting Stent Who Developed Acute Tirofiban-Related Thrombocytopenia.
    Kabadi RA; Danelich IM; Entwistle JW; Marhefka GD; Reeves G; Boyle AJ; Qureshi AM
    Pharmacotherapy; 2019 Apr; 39(4):521-525. PubMed ID: 30644585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cangrelor in cardiogenic shock and after cardiopulmonary resuscitation: A global, multicenter, matched pair analysis with oral P2Y
    Droppa M; Vaduganathan M; Venkateswaran RV; Singh A; Szumita PM; Roberts RJ; Qamar A; Hack L; Rath D; Gawaz M; Fuernau G; de Waha-Thiele S; Desch S; Schneider S; Ouarrak T; Jaffer FA; Zeymer U; Thiele H; Bhatt DL; Geisler T
    Resuscitation; 2019 Apr; 137():205-212. PubMed ID: 30790690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel use of cangrelor in pediatrics: A pilot cohort study demonstrating use in ventricular assist devices.
    Fahnhorst SE; Beasley G; Goldberg JF; Martinez HR; Ryan KA; Towbin JA; Boston U; Absi M
    Artif Organs; 2021 Jan; 45(1):38-45. PubMed ID: 33180355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial.
    O'Donoghue ML; Bhatt DL; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Prats J; Liu T; Deliargyris EN; Mahaffey KW; White HD; Harrington RA;
    Circulation; 2016 Jan; 133(3):248-55. PubMed ID: 26762525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cangrelor for the treatment of arterial thrombosis: pharmacokinetics/pharmacodynamics and clinical data.
    Tamborini Permunian E; Riva N; Guasti L; Squizzato A
    Expert Opin Drug Metab Toxicol; 2015 Apr; 11(4):625-37. PubMed ID: 25728292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]).
    White HD; Bhatt DL; Gibson CM; Hamm CW; Mahaffey KW; Price MJ; Steg PG; Stone GW; Cortese B; Wilensky M; Deliargyris EN; Liu T; Prats J; Harrington RA
    JACC Cardiovasc Interv; 2015 Mar; 8(3):424-433. PubMed ID: 25703887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data.
    Steg PG; Bhatt DL; Hamm CW; Stone GW; Gibson CM; Mahaffey KW; Leonardi S; Liu T; Skerjanec S; Day JR; Iwaoka RS; Stuckey TD; Gogia HS; Gruberg L; French WJ; White HD; Harrington RA;
    Lancet; 2013 Dec; 382(9909):1981-92. PubMed ID: 24011551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implantable left ventricular assist devices as initial therapy for refractory postmyocardial infarction cardiogenic shock.
    Pawale A; Pinney S; Ashley K; Flynn R; Milla F; Anyanwu AC
    Eur J Cardiothorac Surg; 2013 Aug; 44(2):213-6. PubMed ID: 23364853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cangrelor in Older Patients Undergoing Percutaneous Coronary Intervention: Findings From CHAMPION PHOENIX.
    Cavender MA; Bhatt DL; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Prats J; Elkin S; Deliargyris EN; Mahaffey KW; White HD; Harrington RA;
    Circ Cardiovasc Interv; 2017 Aug; 10(8):. PubMed ID: 28801539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet inhibition with cangrelor in patients undergoing PCI.
    Harrington RA; Stone GW; McNulty S; White HD; Lincoff AM; Gibson CM; Pollack CV; Montalescot G; Mahaffey KW; Kleiman NS; Goodman SG; Amine M; Angiolillo DJ; Becker RC; Chew DP; French WJ; Leisch F; Parikh KH; Skerjanec S; Bhatt DL
    N Engl J Med; 2009 Dec; 361(24):2318-29. PubMed ID: 19915221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
    Greenbaum AB; Grines CL; Bittl JA; Becker RC; Kereiakes DJ; Gilchrist IC; Clegg J; Stankowski JE; Grogan DR; Harrington RA; Emanuelsson H; Weaver WD
    Am Heart J; 2006 Mar; 151(3):689.e1-689.e10. PubMed ID: 16504633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cangrelor-supported primary percutaneous coronary intervention in a patient with cardiogenic shock due to left main acute occlusion.
    Siciliano R; Canonico ME; Talanas G; Saba PS; Parodi G
    J Cardiovasc Med (Hagerstown); 2020 Aug; 21(8):616-617. PubMed ID: 32520863
    [No Abstract]   [Full Text] [Related]  

  • 16. Cangrelor: a novel intravenous antiplatelet agent with a questionable future.
    Waite LH; Phan YL; Spinler SA
    Pharmacotherapy; 2014 Oct; 34(10):1061-76. PubMed ID: 25123696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of the percutaneous left ventricular assist device in patients with severe refractory cardiogenic shock as a bridge to long-term left ventricular assist device implantation.
    Idelchik GM; Simpson L; Civitello AB; Loyalka P; Gregoric ID; Delgado R; Kar B
    J Heart Lung Transplant; 2008 Jan; 27(1):106-11. PubMed ID: 18187095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.
    Westman PC; Lipinski MJ; Torguson R; Waksman R
    Cardiovasc Revasc Med; 2017 Mar; 18(2):79-85. PubMed ID: 28089137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of Intravenous Cangrelor Administration for Antiplatelet Bridging in Hospitalized Patients: A Retrospective Study.
    Johnson BV; Horton ER; Domenico C; Nathan AS; Fanaroff AC; Acker MA; Kolansky DM
    J Invasive Cardiol; 2021 Dec; 33(12):E998-E1003. PubMed ID: 34817395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cangrelor for treatment during percutaneous coronary intervention.
    Oestreich JH; Dobesh PP
    Future Cardiol; 2014 Mar; 10(2):201-13. PubMed ID: 24762247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.